C-CBKUtransdermal delivery, curcumin, linker chemistry
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop a hypertension program using Vascarta's listed Quesceptor technology/product candidate.
Not disclosed in supplied material beyond listing as a hypertension pipeline program.
Listed on Vascarta research pipeline as a hypertension program.
Develop a program for brain cancer/glioblastoma.
Not disclosed in supplied material beyond pipeline listing.
Listed on Vascarta research pipeline as a brain cancer/glioblastoma program.
Develop a program for pancreatic cancer.
Not disclosed in supplied material beyond pipeline listing.
Listed on Vascarta research pipeline as a pancreatic cancer program.
Attenuate cisplatin-induced neuropathy associated with breast cancer treatment models.
Novel transdermal curcumin tested in a mouse model of breast cancer with cisplatin-induced neuropathy.
2026 publication/abstract on attenuation of cisplatin-induced neuropathy in a mouse model.
Preserve endothelial barrier function under high-dose inflammatory injury conditions.
Novel transdermal curcumin therapeutic tested in a high-dose LPS rat model.
2023 publication on endothelial barrier function preservation in a high-dose LPS rat model.
Reported preservation of endothelial barrier function in the high-dose LPS rat model.
Evaluate transdermal curcumin for anti-aging, dementia-adjacent, and healthspan-related outcomes.
Transdermal curcumin treatment assessed across multiple healthspan indices in rodent models of normal aging and hypertension.
2025 publication on salutary effects of transdermal curcumin on multiple healthspan indices.
Investigate transdermal curcumin effects relevant to hypertension and healthspan-related physiology.
Transdermal curcumin treatment in rodent models of normal aging and hypertension.
2025 publication on healthspan indices in rodent models of normal aging and hypertension.
Preserve stored red blood cells and reverse oxidative injury during blood storage.
Curcumin-based gel formulation used to deliver curcumin into red blood cells during storage and oxidative injury models.
2024 Scientific Reports publication on blood storage biopreservation and reversal of oxidative injury.
Reported reduced ferryl hemoglobin, recovery of ATP, reduced protein carbonylation, prevention of band 3 phosphorylation, and approximately 10% longer circulation of aged RBCs in a guinea pig model when treated at start of storage.
Reduce knee pain in adults with knee osteoarthritis using topical/transdermal curcumin delivery.
Randomized, double-blind, placebo-controlled study of topical curcumin formulation VAS-101.
2026 publication reporting a randomized controlled knee osteoarthritis study.
Address sickle cell disease pathobiology, chronic pain, red blood cell instability, inflammation, oxidative stress, and cardiac bioenergetic impairment.
Topical/transdermal curcumin gel tested in humanized sickle cell and Berkeley sickle cell mouse models.
2026 publication on cardiac mitochondrial bioenergetics in Berkeley sickle cell mice, following 2025 publication on sickle cell pathobiology and pain.
Reported improved mitochondrial respiration and oxidative stress parameters in cardiac tissue; earlier study reported reduced pain hypersensitivity, improved RBC ATP and stability markers, decreased inflammatory cytokines, and reduced mast cell activation.